Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

NCT03544125 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

3

Enrollment

OTHER

Sponsor class

Conditions

Anatomic Stage IV Breast Cancer AJCC v8
Estrogen Receptor Negative
HER2/Neu Negative
Progesterone Receptor Negative
Prognostic Stage IV Breast Cancer AJCC v8
Triple-Negative Breast Carcinoma

Interventions

BIOLOGICAL: Durvalumab
DRUG: Olaparib

Sponsor

OHSU Knight Cancer Institute

Collaborators

[object Object]
[object Object]